Liquid biopsy for prostate cancer diagnosis
Part of Cancer clinical trials.
This study uses a blood test to detect prostate cancer more accurately than traditional methods. It looks for genetic material from cancer cells to help decide if a prostate biopsy is needed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your PSA level is above 4 ng/dL.
- Your doctor suspects prostate cancer based on a physical exam, ultrasound, or MRI.
- You are willing to have a prostate biopsy.
- You have not been diagnosed with prostate cancer before.
- You have not had another type of cancer in the past two years.
- You do not have a serious medical condition that could interfere with the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study explores whether a simple blood test that looks at tiny particles called exosomes can help diagnose prostate cancer, possibly reducing the need for biopsies. If you have higher PSA levels and are scheduled for a biopsy, this trial might be a fit.
This trial studies a blood test that looks for tumor DNA in men with high-risk or advanced prostate cancer. It may help doctors understand the cancer better and guide treatment decisions.
This study uses a simple blood test to look for microRNA patterns that may help spot prostate cancer earlier and avoid unnecessary biopsies. If you have elevated PSA or suspicious findings, this test might give more information about your risk.
This study tests a new blood test (Proclarix) that may help doctors decide if a prostate biopsy is needed. It is for men with a slightly elevated PSA who are already considering a biopsy.
This study uses a new artificial intelligence test to look for tiny amounts of cancer DNA in your blood. It aims to help catch prostate cancer earlier, when it may be easier to treat.
This study looks at using a simple blood test (liquid biopsy) to read tumor DNA and understand how it could affect treatment decisions. It is for adults with metastatic prostate cancer who are about to start, are receiving, or recently finished treatment.
Hear when a new Clinically Significant Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.